Literature DB >> 15386695

The importance of news media in pharmaceutical risk communication: proceedings of a workshop.

Felicia E Mebane1.   

Abstract

In response to mass media's role in the national and global system of pharmaceutical risk communication, the Centers for Education and Research on Therapeutics (CERTs) convened a 'think tank' session on the 'Importance of Media in Pharmaceutical Risk Communication'. Prominent journalists and experts from the pharmaceutical industry, academia, medical practice and government were invited to consider the benefits and challenges of improving the way we communicate the benefits and risks of therapeutics via mass media, especially news media. Workshop discussions revealed a paucity of systematic research directed towards understanding how and why news media report on therapeutic risk, the impact of this coverage and how coverage can be improved. Consequently, participants produced a research agenda capturing the key aspects of the flow of information around this topic, including the meaning of risk, how news audiences process and use therapeutic risk information in the news, how and why news organizations report on therapeutic risk, and the role and impact of the pharmaceutical industry, government officials and academic researchers as sources of therapeutic risk information. The workshop ended with a discussion on action items addressing what news professionals, representatives of regulatory agencies and the medical products industry, and academic researchers can and should do to enable news media to effectively report therapeutic risk information. In sum, this proceedings report provides an outline for developing mass media risk communication research, influencing the practices of journalists and expert sources and ultimately, improving the quality of the public's life. Copyright (c) 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2005        PMID: 15386695     DOI: 10.1002/pds.993

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  6 in total

1.  Public pharmacovigilance communication: a process calling for evidence-based, objective-driven strategies.

Authors:  Priya Bahri
Journal:  Drug Saf       Date:  2010-12-01       Impact factor: 5.606

2.  Risk perception in drug therapy.

Authors:  J K Aronson
Journal:  Br J Clin Pharmacol       Date:  2006-08       Impact factor: 4.335

3.  A 10-year analysis of the effects of media coverage of regulatory warnings on antidepressant use in The Netherlands and UK.

Authors:  Juan Francisco Hernandez; Aukje K Mantel-Teeuwisse; Ghislaine J M W van Thiel; Svetlana V Belitser; Jan Warmerdam; Vincent de Valk; Jan A M Raaijmakers; Toine Pieters
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

4.  Publication trends in newspapers and scientific journals for SSRIs and suicidality: a systematic longitudinal study.

Authors:  J F Hernandez; A K Mantel-Teeuwisse; G J M W van Thiel; S V Belitser; J A M Raaijmakers; T Pieters
Journal:  BMJ Open       Date:  2011-12-06       Impact factor: 2.692

5.  Pharmaceutical company perspectives on current safety risk communications in Japan.

Authors:  Hisashi Urushihara; Gen Kobashi; Hideaki Masuda; Setsuko Taneichi; Michiko Yamamoto; Takeo Nakayama; Koji Kawakami; Tsutomu Matsuda; Kaori Ohta; Hiroki Sugimori
Journal:  Springerplus       Date:  2014-01-24

6.  Advancing the field of pharmaceutical risk minimization through application of implementation science best practices.

Authors:  Meredith Y Smith; Elaine Morrato
Journal:  Drug Saf       Date:  2014-08       Impact factor: 5.606

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.